Literature DB >> 1689891

Pathologic observations in human allograft recipients treated with FK 506.

A J Demetris1, J J Fung, S Todo, B Banner, T Zerbe, G Sysyn, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1689891      PMCID： PMC2903856     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  20 in total

1.  Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine.

Authors:  N Murase; S Todo; P H Lee; H S Lai; F Chapman; M A Nalesnik; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

2.  Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids.

Authors:  S Todo; A J Demetris; Y Ueda; O Imventarza; K Okuda; A Casavilla; S Cemaj; A Ghalab; V Mazzaferro; B S Rhoe
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

3.  Orthotopic liver transplantation in dogs receiving FK-506.

Authors:  S Todo; L Podesta; P ChapChap; D Kahn; C E Pan; Y Ueda; K Okuda; O Imventarza; A Casavilla; A J Demetris
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

4.  Observations about FK-506 in primates.

Authors:  R Calne; D S Collier; S Thiru
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

5.  Toxicology of FK-506 in the Lewis rat.

Authors:  M A Nalesnik; S Todo; N Murase; S Gryzan; P H Lee; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

6.  Kidney transplantation in the dog receiving FK-506.

Authors:  D S Collier; S Thiru; R Calne
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

7.  Heterotopic heart transplantation in the rat receiving FK-506.

Authors:  S M Lim; S Thiru; D J White
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

8.  Orthotopic liver transplantation: a pathological study of 63 serial liver biopsies from 17 patients with special reference to the diagnostic features and natural history of rejection.

Authors:  D C Snover; R K Sibley; D K Freese; H L Sharp; J R Bloomer; J S Najarian; N L Ascher
Journal:  Hepatology       Date:  1984 Nov-Dec       Impact factor: 17.425

9.  Biopsy-directed immunosuppression following hepatic transplantation in man.

Authors:  J W Williams; T G Peters; S R Vera; L G Britt; S J van Voorst; R C Haggitt
Journal:  Transplantation       Date:  1985-06       Impact factor: 4.939

10.  Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases.

Authors:  E S Zafrani; K G Ishak; C Rudzki
Journal:  Dig Dis Sci       Date:  1979-05       Impact factor: 3.199
View more
  15 in total

1.  Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction.

Authors:  A C Tsamandas; S M Pham; E C Seaberg; O Pappo; R L Kormos; A Kawai; B P Griffith; A Zeevi; R Duquesnoy; J J Fung; T E Starzl; A J Demetris
Journal:  J Heart Lung Transplant       Date:  1997-07       Impact factor: 10.247

2.  A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.

Authors:  J Fung; K Abu-Elmagd; A Jain; R Gordon; A Tzakis; S Todo; S Takaya; M Alessiani; A Demetris; O Bronster
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine.

Authors:  A J Demetris; B Banner; J Fung; R Shapiro; M Jordan; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

4.  Current status of FK 506 in liver transplantation.

Authors:  J J Fung; S Todo; A Tzakis; M Alessiani; K Abu-Elmagd; A Jain; O Bronster; M Martin; R Gordon; T E Starzl
Journal:  Transplant Proc       Date:  1991-06       Impact factor: 1.066

5.  Overview of FK506 in transplantation.

Authors:  J J Fung; K Abu-Elmagd; S Todo; R Shapiro; A Tzakis; M Jordan; J Armitage; A Jain; M Alessiani; M Martin
Journal:  Clin Transpl       Date:  1990

6.  FK 506 used as rescue therapy for human liver allograft recipients.

Authors:  A J Demetris; J J Fung; S Todo; J McCauley; A Jain; S Takaya; M Alessiani; K Abu-Elmagd; D H Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

7.  The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine.

Authors:  P S Randhawa; R Shapiro; M L Jordan; T E Starzl; A J Demetris
Journal:  Am J Surg Pathol       Date:  1993-01       Impact factor: 6.394

Review 8.  FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects.

Authors:  P E Wallemacq; R Reding
Journal:  Clin Chem       Date:  1993-11       Impact factor: 8.327

Review 9.  Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts.

Authors:  A J Demetris; N Murase; R G Lee; P Randhawa; A Zeevi; S Pham; R Duquesnoy; J J Fung; T E Starzl
Journal:  Ann Transplant       Date:  1997       Impact factor: 1.530

Review 10.  Kidney transplantation in highly sensitized patients: reappraisal of etiology, evaluation, and management protocols.

Authors:  R Indudhara; R B Khauli
Journal:  World J Urol       Date:  1996       Impact factor: 4.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.